Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016–2025) - Top-Institutions - MDSpire

Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016–2025)

  • By

  • Bing Guo

  • Ge Zhang

  • Shengpeng Sang

  • Xianfen Ma

  • Huanpeng Qi

  • June 2, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    University of Texas MD Anderson Cancer Center
    University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #2

    Mass General Cancer Center
    Mass General Cancer Center

    Boston, Massachusetts

    Key Differentiators

    • Oncology

Original Source(s)

Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016–2025)

  • by Bing Guo, Ge Zhang, Shengpeng Sang, Xianfen Ma, Huanpeng Qi

  • June 2, 2026

Related Content

Case Report: Intramedullary solitary fibrous tumor at the C7-T1 level diagnosed by STAT6 and treated with maximal safe resection

SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

Leveraging deep learning and explainable AI for effective liver tumor classification from CT scan images